![](/images/graphics-bg.png)
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Joint Authors
Kampan, Nirmala
Madondo, Mutsa Tatenda
McNally, Orla M.
Quinn, Michael
Plebanski, Magdalena
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-21, 21 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-06-07
Country of Publication
Egypt
No. of Pages
21
Main Subjects
Abstract EN
Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management.
A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit.
Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.
American Psychological Association (APA)
Kampan, Nirmala& Madondo, Mutsa Tatenda& McNally, Orla M.& Quinn, Michael& Plebanski, Magdalena. 2015. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. BioMed Research International،Vol. 2015, no. 2015, pp.1-21.
https://search.emarefa.net/detail/BIM-1055384
Modern Language Association (MLA)
Kampan, Nirmala…[et al.]. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. BioMed Research International No. 2015 (2015), pp.1-21.
https://search.emarefa.net/detail/BIM-1055384
American Medical Association (AMA)
Kampan, Nirmala& Madondo, Mutsa Tatenda& McNally, Orla M.& Quinn, Michael& Plebanski, Magdalena. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-21.
https://search.emarefa.net/detail/BIM-1055384
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1055384